SEC Form 4 
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0287	
Estimated average burden	
hours per response:	0.5	

	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
1. Name and Address of Reporting Person*
Marquet Magda	

(Last)	(First)	(Middle)	
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.	
10628 SCIENCE CENTER DRIVE, SUITE 250	

(Street) 
SAN DIEGO	CA	92121	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
Arcturus Therapeutics Holdings Inc. [ ARCT ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
X	Director		10% Owner	
	Officer (give title below)		Other (specify below)	

	3. Date of Earliest Transaction (Month/Day/Year)
09/13/2019 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) 
X	Form filed by One Reporting Person	
	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	09/13/2019		P		2,300	A	$10.58 	22,720	I	Via Alma Life Sciences, LLC	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Explanation of Responses:	
Remarks:	
Exhibit 24 - Power of Attorney	
	/s/ Ilan Katz, attorney-in-fact	09/17/2019	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
                                                                      EXHIBIT 24

                               POWER OF ATTORNEY
       FOR SEC FILINGS ON FORMS ID, 3, 4, 5, 144, SCHEDULES 13D and 13G
                          IN RESPECT OF SECURITIES OF
                      ARCTURUS THERAPEUTICS HOLDINGS INC.

     The undersigned hereby constitutes and appoints each of Jeffrey Baumel and
Ilan Katz as his or her true and lawful attorneys-in-fact and agents, each with
full power of substitution and resubstitution for him or her in his or her name
and stead in any and all capacities, to sign and file for and on his or her
behalf, in respect of any acquisition, disposition or other change in ownership
of any Common Stock or derivative securities thereof of Arcturus Therapeutics
Holdings Inc. (the "Company"), the following:

     (i)   any Form ID to be filed with the Securities and Exchange Commission
          (the "SEC");

     (ii)  any Initial Statement of Beneficial Ownership of Securities on Form 3
           to be filed with the SEC;

     (iii) any Statement of Changes of Beneficial Ownership of Securities on
           Form 4 to be filed with the SEC;

     (iv)  any Annual Statement of Beneficial Ownership of Securities on Form 5
           to be filed with the SEC;

     (v)   any Notice of Proposed Sale of Securities on Form 144 to be filed
           with the SEC;

     (vi)  and any other forms or reports the undersigned may be required to
           file in connection with the undersigned's ownership, acquisition or
           disposition of securities of the Company, including Schedules 13G and
           13D; and

     (vii) any and all agreements, certificates, receipts, or other documents in
           connection therewith. The undersigned hereby gives full power and
           authority to each attorney-in-fact to seek and obtain as the
           undersigned's representative and on the undersigned's behalf,
           information on transactions in the Company's securities from any
           third party, including brokers, employee benefit plan administrators
           and trustees, and the undersigned hereby authorizes any such person
           to release such information to the undersigned and approves and
           ratifies any such release of information. The undersigned hereby
           grants unto each attorney-in-fact and agent full power and authority
           to do and perform each and every act and thing requisite and
           necessary in connection with such matters and hereby ratifies and
           confirms all that any such attorney-in-fact and agent or substitute
           may do or cause to be done by virtue hereof. The undersigned
           acknowledges that:

          (i)   neither the Company nor any of such attorney-in-fact assumes (i)
                any liability for the undersigned's responsibility to comply
                with the requirement of the Securities Exchange Act of 1934, as
                amended (the "Exchange Act"), (ii) any liability of the
                undersigned for any failure to comply with such requirements or
                (iii) any obligation or liability of the undersigned for profit
                disgorgement under Section 16(b) of the Exchange Act; and

          (ii)  this Power of Attorney does not relieve the undersigned from
                responsibility for compliance with the undersigned's obligations
                under the Exchange Act, including without limitation the
                reporting requirements under Section 16 of the Exchange Act.
                This Power of Attorney shall remain in full force and effect
                until revoked by the undersigned in a signed writing delivered
                to such attorney-in-fact.

                            [Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney.

Date:  August 15, 2019           /s/ Magda Marquet
                                 -----------------
                                 Name: Magda Marquet